Teva and its partner, Antares have received approval of a Supplemental New Drug Application (sNDA), which added needle-free injection to its Tev-Tropin, human growth hormone (hGH) drug label.
Teva would market the Antares needle-free injector as the Tev-Tropin Tjet Injector system.
Larry Downey, Head of North America Brand Pharmaceuticals division at Teva, said: We are pleased to add this new technology to our growing portfolio through our successful partnership with Antares and to offer patients a less invasive delivery system.”
Paul Wotton, President and CEO of Antares, said: This is the first product approval stemming from our portfolio of product collaborations with Teva and is a very exciting milestone for the company. We look forward to the launch of this product by Teva.